Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Matosinhos – page 18

691 clinical trials in Matosinhos, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Matosinhos at a glance
691
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

691 trials in Matosinhos

Open in trial search

Study on the Long-Term Safety of Futibatinib and Fulvestrant for Patients with Malignant Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Taiho Oncology Inc.

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Obrixtamig
  • Sponsor:Boehringer Ingelheim International GmbH

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

B-cell lymphoma+1

Recruiting

Long-term Study of Ibrutinib for Patients with B-cell Non-Hodgkin's Lymphoma and Chronic Graft Versus Host Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study on the Safety and Effectiveness of Quizartinib for Children with Newly Diagnosed FLT3-ITD Positive AML and Normal NPM1

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Aortic stenosis

Recruiting

Study on Ticagrelor and Aspirin for Patients with Severe Aortic Stenosis After Heart Valve Replacement

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Biomedica Galicia Sur

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Vericiguat for Children with Heart Failure Due to Left Ventricular Systolic Dysfunction

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Matosinhos

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on Frontotemporal Dementia and various forms of Multiple Sclerosis, including primary progressive and secondary progressive variants. Studies are evaluating novel therapeutic approaches and long-term treatment options.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Epilepsy Interventions

Clinical investigations include assessment of new compounds for refractory focal onset epilepsy and progressive neurological conditions.

02 Respiratory Medicine

Comprehensive studies addressing Pulmonary Fibrosis and chronic respiratory conditions. Research focuses on innovative treatments for chronic rhinosinusitis and progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis
  • Chronic Rhinosinusitis
  • COPD Management

Trials aim to improve lung function and reduce disease progression in various respiratory conditions.

03 Cardiovascular Studies

Advanced research in Heart Failure and stroke prevention, particularly focusing on patients with atrial fibrillation. Studies evaluate new treatment combinations and preventive strategies.

  • Stroke Prevention
  • Heart Failure Management
  • Systemic Embolism Prevention

Research includes comparative studies of new medications for cardiac conditions and prevention strategies.

04 Oncology Research

Targeted studies on Neuroendocrine Cancers, including small cell lung cancer and other specialized cancer types. Research focuses on advanced treatment options for patients with limited therapeutic alternatives.

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
  • Advanced Cancer Therapies

Trials evaluate new therapeutic approaches for patients who have progressed after standard treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.